About TMRTransparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services.. Based on type of administration, the global chronic idiopathic constipation treatment market has been categorized into oral and parenteral. The frequency may be reduced to less than three times a week. North America is expected to hold major share of the chronic idiopathic constipation treatment market owing to significant percentage of population suffering from CIC.The infrequent bowel movement could be due to dry, hard stool leading to chronic idiopathic constipation. Mexico and Brazil are the high potential growth markets in Latin America because of improvement of medical infrastructure. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information. It has been observed more common in adult aged or older people. In terms of distribution channel, the market has been divided into independent pharmacies, drug stores, and hospital pharmacies.com/sample/sample. The global chronic idiopathic constipation treatment market has been segmented based on type, type of administration, region, and distribution channel. If motility is slower down, the stool movement can be difficult to pass which results in infrequent bowel movement. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs https://www.toiletstool.net/ rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. If colon absorbs more water, the stool can be hard, dry, and difficult to pass. Europe was the second largest market for chronic idiopathic constipation treatment due to high prevalence rate. The repeatedly occurring most common symptoms include abdominal discomfort, bloating, gas pain, incomplete evacuation, hard stool, and straining at the time of bowel movement. A survey found chronic idiopathic constipation common in 56% women, 44% men. The data obtained from the National Center for Biotechnology Information revealed that 4 million people in the U.Constipation can be defined as reduced stool frequency or difficulty in passing stool. The rate at which muscles in colon contract to help pass through the stool is referred as motility. Abbott Gut-Health Survey reported that 14% people in India suffer from constipation. Often chronic idiopathic constipation is indicated with multiple symptoms. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms.Chronic idiopathic constipation occurs without an identifiable cause. As cause of constipation is unclear, it is called idiopathic constipation.Several factors contribute to constipation including change in water balance and motility in colon. have frequent constipation, corresponding to prevalence of 2%. India, China, and Japan are likely to fuel the growth of the global chronic idiopathic constipation market in Asia Pacific. Increasing incidence, prevalence, and growing awareness can be considered the major factors driving the global chronic idiopathic constipation treatment market. Many times the cause of constipation is unclear or unknown and not because of underlying illness or medication., Synergy Pharmaceuticals, Inc. Fleet Company, Inc. B. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. In terms of type, the market has been segmented into pharmacological treatment and non-pharmacological treatment. The laxatives and stool softeners segments are expected to account for major share of the global chronic constipation market during the forecast period in comparison to other class of drugs.Major players in the global chronic idiopathic constipation treatment market include Boehringer Ingelheim GmbH, Bayer AG, C. This slow movement results in more water absorption and leads to hard, dry stool. Pharmacological treatment consists of stool softener, laxatives, bulk forming agents, emollients, osmotic agents, chloride channel activators, and others., Actavis, Ironwood Pharmaceuticals, Cosmo Pharmaceuticals, and Sucampo Pharmaceuticals, Inc.php?flag. Geographically, the global chronic idiopathic constipation treatment market has been segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Rising prescription opioid consumption, increasing geriatric population, rising health care expenditure, launch of targeted medicines, and growing awareness are likely to drive the chronic idiopathic constipation treatment market during the forecast period. Out of patients suffering from chronic idiopathic constipation only 12% are medically diagnosed and 40% are actively seeking treatment.
コメント